| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d249a4698cb89e3eb811d2f47114b5e4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-135 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6857
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b108bd9af849e2b24382ab6037850023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6f9cafcaea187d9d502fe804ff961dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba301d357f9400653067198f7f77bbe7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e979b2b76b4037cdc899efb8696d42a3 |
| publicationDate |
2008-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20080025174-A |
| titleOfInvention |
Antibody Preparations with Optimized Aggregation and Fragmentation Profiles |
| abstract |
The present invention provides a method for optimizing the production and purification of an antibody formulation suitable for immunospecific binding to an antigen of interest and for parenteral administration to a subject, wherein the formulation is an antibody component upon prolonged storage. Stability is increased due to the decomposition and reduction of aggregation. Such methods are produced by less optimized methods, including less stringent or more readily available transport / storage conditions, less frequent or smaller doses in therapeutic, prophylactic, and diagnostic use of the formulation. Provided are formulations that provide a number of advantages over formulations. The invention further provides methods of using the formulations of the invention. |
| priorityDate |
2005-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |